Amarin News

He probably thinks earlier than that.. - Schnuz May 22, 2013 Nope. I mean FDA will reject Vascepa for the "Anchor" mixed dyslipidemia indication.

Amarin Corporation has been struggling a lot lately as retail channel prescription data for its EPA capsule Vascepa imply that the drug is starting to slow down its momentum in the MARINE indication .

Interestingly enough, the two biotech stories that I watch both had patent approval news today.

Amarin had been trading bullish on the heels of their quarterly conference call two weeks ago where they reported a continued increase in Vascepa sales and $2.3 million in recognized Vascepa revenues.

The healthcare sector has been facing significant challenges over the last few years.

Growing Stock Report expands its NASDAQ Gainers Weekly Watch List adding Biogen Idec Inc.

Amarin Co. plc Receives "Outperform" Rating from Leerink Swann Leerink Swann reissued their outperform rating on shares of Amarin Corporation plc in a research report released on Thursday morning, Stock Ratings Network reports.

Last week was quite decent for Amarin Corporation investors, who saw a 6% rally last Friday in reaction to the company's Q1 2013 financial results.

The analysts wrote, "Omthera is developing Epanova, an ultra-pure mixture of the omega-3 fish oils EPA and DHA.

AMRN investors should be aware of a decrease in support from the world's most elite money managers of late.

Welcome to Amarin Corporations Conference Call to discuss its first quarter 2013 financial and operating results.

Nothing has come easy for Amarin . This manufacturer of the ultra-pure fish oil treatment Vascepa has garnered a devoted following of investors who believe that this is not just the next Lovaza acquired in 2007 for $1.7 billion by buying Reliant Pharmaceuticals), but even more.

Senior managers of Amarin Corp. plc, a biotech company with research headquarters in Groton, will discuss the company's first-quarter financial results at 4:30 p.m. Thursday during a conference call.

Amarin longs don't really like me. The same kind of way that Carl Icahn and Bill Ackman "don't really" like each other.

The bull argument for Amarin's Vascepa is simple: it works better than Lovaza, it doesn't have the negative aspects, it doesn't have an atrial fibrillation warning, it is applying for approval to be marketed to a ten times larger patient population, and the combo drug looks to be the best treatment for hyperlipidemia ever created, per the patent ... (more)

Amarin Corporation is one of the most controversial and debated stocks in recent memory.